- Home
- FCNCA vs BIIB Comparison
FCNCA vs BIIB Comparison
Compare FCNCA & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCNCA
- BIIB
- Stock Information
- Founded
- FCNCA 1898
- BIIB 1978
- Country
- FCNCA United States
- BIIB United States
- Employees
- FCNCA N/A
- BIIB N/A
- Industry
- FCNCA Major Banks
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- FCNCA Finance
- BIIB Health Care
- Exchange
- FCNCA Nasdaq
- BIIB Nasdaq
- Market Cap
- FCNCA 27.2B
- BIIB 25.1B
- IPO Year
- FCNCA N/A
- BIIB 1991
- Fundamental
- Price
- FCNCA $2,197.92
- BIIB $160.92
- Analyst Decision
- FCNCA Buy
- BIIB Buy
- Analyst Count
- FCNCA 8
- BIIB 25
- Target Price
- FCNCA $2,153.63
- BIIB $258.57
- AVG Volume (30 Days)
- FCNCA 100.0K
- BIIB 1.6M
- Earning Date
- FCNCA 01-24-2025
- BIIB 10-30-2024
- Dividend Yield
- FCNCA 0.36%
- BIIB N/A
- EPS Growth
- FCNCA N/A
- BIIB 10.05
- EPS
- FCNCA 174.55
- BIIB 11.06
- Revenue
- FCNCA $9,364,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- FCNCA N/A
- BIIB N/A
- Revenue Next Year
- FCNCA N/A
- BIIB N/A
- P/E Ratio
- FCNCA $12.55
- BIIB $14.55
- Revenue Growth
- FCNCA 44.77
- BIIB N/A
- 52 Week Low
- FCNCA $1,363.97
- BIIB $153.62
- 52 Week High
- FCNCA $2,388.78
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- FCNCA 51.88
- BIIB 37.88
- Support Level
- FCNCA $2,162.98
- BIIB $158.44
- Resistance Level
- FCNCA $2,329.02
- BIIB $165.29
- Average True Range (ATR)
- FCNCA 57.18
- BIIB 4.00
- MACD
- FCNCA -14.40
- BIIB 1.10
- Stochastic Oscillator
- FCNCA 23.82
- BIIB 32.82
About FCNCA First Citizens BancShares Inc.
First Citizens BancShares Inc is the bank holding company of First Citizens Bank & Trust Company. FCB was founded as the Bank of Smithfield in North Carolina and has expanded through both de novo branching and acquisitions. FCB currently operates in nearly half of the continental United States, but principally takes deposits in the Carolinas. The bank's operations have historically been influenced by the Holding family, which has traditionally held executive and director positions, as well as controlling a large percentage of its outstanding stock. FCB provides a wide range of retail and commercial banking services, including traditional lending and deposit-taking, as well as trust and wealth management. FCB's main source of revenue is net interest income.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.